Ocugen

Ocugen, Inc. (NASDAQ: OCGN), headquartered in Malvern, PA, is a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases. Their breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – “one to many” and their novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. For more information, visit www.ocugen.com.


Ocugen
Public Companies

Ocugen CEO to Address Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity Conference

- by Timothy Alexander

MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company specializing in the discovery, development, and commercialization of gene and cell therapies, biologics, and vaccines, has announced that its Chairman, …

Ocugen CEO to Address Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity Conference Read More

Ocugen
Finance

Ocugen’s Promising Advancements: Q3 2023 Financial Results and Progress in Ophthalmic Gene Therapies, Regenerative Cell Therapies, and Vaccines Portfolio

- by Timothy Alexander

MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN), a frontrunner in the world of biopharmaceuticals, recently disclosed its Q3 2023 financial results and a business update that holds promising news for …

Ocugen’s Promising Advancements: Q3 2023 Financial Results and Progress in Ophthalmic Gene Therapies, Regenerative Cell Therapies, and Vaccines Portfolio Read More